Rectal Cancer Clinical Trial
— NEAPEOfficial title:
Nordic Extended Abdominoperineal Excision (NEAPE) Study, a RCT Comparing a Porcine Acellular Dermal Collagen Implant (Biological Mesh) With a Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
Verified date | May 2023 |
Source | Umeå University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The trial compares two different techniques for reconstruction of the lesser pelvic floor after an extended abdominoperineal excision for locally advanced rectal cancer. The alternative reconstruction techniques in the trial are: - a technique using a gluteus maximus myocutaneous flap or - a technique using an acellular porcine collagen implant (biological mesh) The primary endpoint will be physical performance six months from operation and our hypothesis is that the technique using an acellular porcine implant will cause less impaired physical performance compared to the technique using a myocutaneous flap. The study is interventional, randomized and by definition a comparative effectiveness research project.
Status | Active, not recruiting |
Enrollment | 91 |
Est. completion date | September 30, 2024 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (18 years or older) rectal cancer patients where wide resection of pelvic floor muscles together with rectum and anal canal have made reconstruction of pelvic floor necessary i.e. primary suture of pelvic floor in the midline is not possible. Resection of coccyx is optional. Exclusion Criteria: - Age less than 18 years - Very large resections including partial resection of sacrum and patients considered for bilateral flap reconstruction - Large concomitant resection of vaginal wall where total (vaginal) wound closure is not an option - Expected survival less than one year at operation - Patient do not sign informed consent document |
Country | Name | City | State |
---|---|---|---|
Finland | Oulu University Hospital | Oulu | |
Sweden | Sunderby County Hospital | Luleå | |
Sweden | Skåne Universtiy Hospital | Malmö | |
Sweden | Östersund Hospital | Östersund | |
Sweden | Karolinska University Hospital, Solna | Stockholm | |
Sweden | Umeå University Hospital, Department of Surgical and Perioperative Sciences | Umeå | |
Sweden | Uppsala University Hospital | Uppsala | |
Sweden | Västmanlands Sjukhus Västerås | Västerås |
Lead Sponsor | Collaborator |
---|---|
Umeå University | The Swedish Society of Medicine, Västerbotten County Council, Sweden |
Finland, Sweden,
Haapamaki MM, Pihlgren V, Lundberg O, Sandzen B, Rutegard J. Physical performance and quality of life after extended abdominoperineal excision of rectum and reconstruction of the pelvic floor with gluteus maximus flap. Dis Colon Rectum. 2011 Jan;54(1):101-6. doi: 10.1007/DCR.0b013e3181fce26e. — View Citation
Holm T, Ljung A, Haggmark T, Jurell G, Lagergren J. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg. 2007 Feb;94(2):232-8. doi: 10.1002/bjs.5489. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance in Timed-Stands Test | Timed-Stands test is a combined measure of physical performance depending on at least muscle strength, balance, tenderness of gluteal skin and muscles and co-ordination of motion. | 6 months after surgery | |
Secondary | Change in physical performance | Change in Timed-Stands Test performance | 3, 6 and 12 months after surgery compared with preoperative results | |
Secondary | Primary wound healing assessed with the Southampton Wound Assessment Scale | The Southampton Wound Assessment Scale is a validated measure of wound healing after surgery. | 3 months from operation | |
Secondary | Complications according to classification by Dindo-Clavien | The Dindo-Clavien classification of surgical complications is a validated instrument. | 3, 6 and 12 months after surgery | |
Secondary | Proportion of persistent perineal sinus or fistula | Proportion of patients with the wound healing defect of all patients in the particular study arm | 3, 6 and 12 months after surgery | |
Secondary | Ability to sit | Ability to sit is graded with a scale in three degrees. | 3, 6 and 12 months after surgery | |
Secondary | Change of pain and discomfort in gluteal region measured with VAS | A standard visual analogue scale (VAS) from 0-100 mm is used. | 3, 6 and 12 months after surgery compared to preoperative | |
Secondary | Pain and discomfort in gluteal region, spot measures with VAS | A standard visual analogue scale (VAS) from 0-100 mm is used. | 3, 6 and 12 months after surgery | |
Secondary | Change of quality of life measured with EQ-5D and EORTC forms C30 and CR29 | EQ-5D and EORTC are validated quality of life instruments | 3, 6 and 12 months after surgery compared to preoperative | |
Secondary | Quality of life spot measures | Quality of life at specified time points | 3, 6 and 12 months after surgery | |
Secondary | Length of hospital stay | Length of index hospital stay in days. | Six months after surgery | |
Secondary | Costs of surgical treatment | Hospital expenses converted to US$ | 12 months after surgery | |
Secondary | Quality-adjusted life years (QALYs gained) | Quality adjusted life year (QALY) is calculated using an quality of life utility index at repeated time points. The utility index is adjusted for the relevant background population. | 12 months after surgery | |
Secondary | Local recurrence | Local recurrence of rectal cancer detected by clinical or radiological investigation | Five years after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Active, not recruiting |
NCT02438839 -
Curative Chemoradiation of Low Rectal Cancer
|